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Figure captions: 
 
Figure 1 :  Gaussian distribution of the carnosine content of the gastrocnemius and soleus 
muscle in an adult male population (age range : 19-49 years; n= 93). Data are compiled from 
subjects of previous studies from our laboratory. Carnosine concentration is measured by 
means of proton MRS, as previously described [1], and expressed relative to the water signal. 
 
Figure 2: Putative determinants of the human muscle carnosine content. 
 
Figure 3: Correlation between the carnosine content in the soleus and in the gastrocnemius 
in 93 male subjects as measured by proton MRS. Similar correlations were also found for 
tibialis anterior vs. gastrocnemius and tibialis anterior vs. soleus (data not shown). In almost 
all subjects, carnosine concentrations are higher in gastrocnemius than soleus. Data are the 
same as in figure 1. 
 
Figure 4: Muscle carnosine content before (0w) and after (5w) 5 weeks of oral 
supplementation (4.8 g.day-1) of beta-alanine or placebo in physically active students or in 
trained 400m runners. Data are extracted from previous studies from our laboratory [1;2]. 
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Abstract: 
Carnosine is a dipeptide with a high concentration in mammalian skeletal muscle. It is 
synthesized by carnosine synthetase from the amino acids L-histidine and β-alanine, of 
which the latter is the rate-limiting precursor, and degraded by carnosinase. Recent studies 
have shown that the chronic oral ingestion of β-alanine can substantially (up to 80%) elevate 
the carnosine content of human skeletal muscle. Interestingly, muscle carnosine loading 
leads to improved performance in high-intensity exercise in both untrained and trained 
individuals. Although carnosine is not involved in the classic ATP-generating metabolic 
pathways, this suggests an important role of the dipeptide in the homeostasis of contracting 
muscle cells, especially during high rates of anaerobic energy delivery. Carnosine may 
attenuate acidosis by acting as a pH buffer, but improved contractile performance may also 
be obtained by improved excitation-contraction coupling and defence against reactive 
oxygen species. High carnosine concentrations are found in individuals with a high 
proportion of fast-twitch fibers, because these fibers are enriched with the dipeptide. 
Muscle carnosine content is lower in women, declines with age and is probably lower in 
vegetarians, whose diets are deprived from beta-alanine. Sprint-trained athletes display 
markedly high muscular carnosine, but the acute effect of several weeks of training on 
muscle carnosine is limited. High carnosine levels in elite sprinters are therefore either an 
important genetically-determined talent selection criterion or a result of slow adaptation to 
years of training. Beta-alanine is rapidly developing as a popular ergogenic nutritional 
supplement for athletes worldwide, and the currently available scientific literature suggests 
that its use is evidence-based. However, many aspects of the supplement, such as the 
potential side-effects and the mechanism of action, require additional and thorough 
investigation by the sports science community. 
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Text pages: 
Until recently, relatively little was known about the physiological role of carnosine in skeletal 
muscle, despite the fact that the molecule was discovered more than a century ago and that 
it is one of the most abundant metabolites in muscle cells.  The objective of this review is to 
provide a state-of-the-art overview of the science on carnosine’s role in muscle. The recent 
progress in this area originates from the discovery in 2006 by Roger Harris and co-workers 
that oral beta-alanine supplementation can increase the muscle carnosine content and 
thereby the performance during high-intensity exercise [3;4]. This review aims to discuss the 
potential mechanisms, based on the known biochemical properties of the dipeptide, that 
may underlie the ergogenic effects of carnosine loading. Second, muscle carnosine 
concentration displays a high interindividual variation in humans and in this review we 
describe the possible determinants of this variability. The interaction of carnosine and 
training is discussed. Both the effect of exercise training on the muscle carnosine content, as 
well as the value of beta-alanine as a training aid remain a matter of debate. This review 
contains a number of practical implications for athletes who seek improved exercise 
performance by using beta-alanine.  
In order to provide a comprehensive summary of the currently available knowledge on 
muscle carnosine and beta-alanine supplementation with respect to exercise performance 
and training, a literature search was performed on PubMed and Web of Science using the 
search terms ‘carnosine’ or ‘beta-alanine’ in combination with ‘muscle’, ‘exercise’ or 
‘performance’. This literature overview is based on more than 100 published articles from 
1950 to August 2009 on this topic. 
Metabolic pathways of carnosine 
Carnosine (beta-alynyl-L-histidine) is a dipeptide, combining the proteinogenic amino acid 
histidine with the non-proteinogenic beta-amino acid beta-alanine. Carnosine was first 
identified by the Russian biochemist Vladimir Gulevich in 1900, when he was looking for 
unidentified nitrogen-containing compounds in meat extract. Accordingly, he named the 
discovered molecule carnosine (carnis is Latin for meat/flesh). This name appeared to be 
accurately chosen as carnosine is predominantly present in skeletal muscle tissue of 
mammals and virtually absent from most other organs, except from its heterogeneous 
presence in brain regions. A concise review on carnosine’s discovery and identification is 
written by Alexander A. Boldyrev [5].  
Carnosine is absent from plants (and therefore from vegetarian food) and invertebrates, 
whereas in the animal kingdom it appears in high but varying quantities in muscles from 
different vertebrates [6]. In humans, the muscle concentration of carnosine is 5-8 mM in wet 
weight (or 20-30 mmol/kg dry weight), which is comparable to the concentrations of ATP, 
carnitine or taurine and lower than (phospho)creatine. Carnosine is the only histidine-
containing dipeptide (HCD) found in human muscle, whereas muscles of other 
animals/mammals may also contain methylated analogues of carnosine, namely anserine 
(beta-alanyl-N1-methylhistidine) and balenine/ophidine (beta-alanyl-N3-methylhistidine). 
When comparing the total HCD content in muscles of different animals, humans are 
somewhere in the middle. Some endurance exercise type animals like pigeons and migrating 
birds have lower concentrations (< 5 mM), while other animals that are involved in more 
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burst-like and sprint exercise (chicken, grey-hound dogs, thoroughbred horse) have 
markedly higher concentrations (20-50 mM) [7]. Some of the highest HCD concentrations, 
higher than the concentrations of ATP and CrP combined, have been observed in whale, 
whose exercise profile is characterized by extremely prolonged hypoxic dives and anaerobic 
energy delivery [6]. The specific evolutionary drive of high HCD content in muscles of animals 
involved in anaerobic work, may be of particular importance when trying to understand in 
what exercise conditions carnosine plays a pivotal role. 
The major pathways involved in carnosine metabolism are synthesis and hydrolysis, 
respectively from and to its constituent amino acids [8]. The enzymatic condensation of 
beta-alanine and histidine is catalysed by carnosine synthase (or synthetase), but the 
enzyme is poorly identified and its genetic origin unknown [9]. High activities of carnosine 
synthase have been found in skeletal muscle tissue [6] and in specific regions of the brain, 
such as the olfactory bulb [9]. In humans and horses, β-alanine is considered to be the rate-
limiting precursor of carnosine synthesis. β-alanine can be obtained through the hydrolysis 
of dipeptides extracted from dietary meat or fish and through the degradation of uracil in 
the liver [10]. Bakardjiev and Bauer [11] have shown that the transsarcolemmal transport of 
one molecule of β-alanine requires two sodium ions and one chloride ion. 
The enzymatic hydrolysis of carnosine is catalyzed by carnosinase, of which two forms exist 
in the human body [12]. Serum carnosinase (CN1) is highly active in humans, resulting in the 
mere absence of carnosine from human blood, in contrast to other mammals such as 
rodents who lack serum carnosinase and whose blood contains considerable amounts of 
carnosine [13]. Tissue carnosinase (CN2), also known as cytosolic nonspecific dipeptidase, is 
quantitatively less important for the degradation of carnosine in humans.  
Proposed role of skeletal muscle in whole-body carnosine metabolism 
Literature suggests that skeletal muscle is the major production site and storage site for 
carnosine in the human body. With respect to its storage function, probably more than 99% 
of the body’s carnosine is present in the skeletal muscles, because of the size of the 
musculature (constituting 40-50% of the total body weight) and the high muscle carnosine 
concentration (5-8 mM) compared to its concentration in other carnosine containing tissues, 
such as brain (0.1 mM on average) [5]. The support for the production function comes from 
several lines of evidence. First, the highest rates of carnosine synthase activity are found in 
skeletal muscle tissue, along with the olfactory bulb [5;14]. Second, there is reason to 
believe that very little of the synthesized carnosine in the muscle cells is subsequently 
hydrolyzed again, since carnosinase is virtually absent from muscle [14;15] and there is no 
non-enzymatic degradation process for carnosine. Instead, synthesized carnosine either 
remains present in the muscle cells for long periods, or it is secreted into the circulation 
through a regulated transport process. Evidence for the former was recently shown by 
Baguet et al. [2], who showed that a highly increased concentration of carnosine in human 
calf muscles following beta-alanine supplementation can remain present for >9 weeks 
following cessation of supplementation. Evidence for the regulated carnosine release from 
muscle into the circulation is fragmentary at present. Carnosine can be transported as an 
intact dipeptide across the plasma membrane through proton-coupled oligopeptide 
transporters (PEPT1, PEPT2, PHT) [16-18]. Kamal et al. [19] have recently shown that the 
genetic knockout of PEPT2 in mice results in a decreased tissue carnosine content in spleen, 
kidney and olfactory bulb. Interestingly, the muscle carnosine content was increased rather 
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than decreased in PEPT2 knockout mice, suggesting that release of carnosine from muscle 
was inhibited by PEPT2 deficiency [19]. 
There is some evidence to believe that carnosine metabolism (synthesis, degradation, 
release) increases upon muscle contractile activity and exercise. Nagai et al. [20] observed 
elevated circulating carnosine levels and increased carnosine synthase activity in 
gastrocnemius muscle when rats were exercising in a running wheel. Also in humans, 
carnosine concentration markedly increases in the skeletal muscle interstitium during leg 
extension exercise at 20W, as determined by microdialysis [21]. Although some researchers 
believe that the contraction-induced release of carnosine by muscles is a measure of muscle 
damage and exertional rhabdomyolysis [21-23], Nagai et al. [20] have proposed that 
carnosine release from muscle is a regulated process. The fact that proton accumulation 
(acidosis) can stimulate the proton-driven dipeptide transporter (PEPT2) provides one 
possible mechanism as to why muscles would release/secrete more carnosine during 
contractions than at rest. The observation that the histidine concentration increases in 
parallel with carnosine in human muscle interstitium [23] suggests that at least a portion of 
the contraction-induced release of carnosine from muscle is immediately hydrolyzed by the 
serum carnosinase present in the interstitium/circulation in humans. In vitro animal 
experiments have suggested that the muscle carnosine concentration decreases following a 
period of contractions [24], further supporting the hypothesis of contraction-induced 
carnosine release. Finally, it is suggested that exercise training increases the activity of 
serum carnosinase in rats [20] and humans [25;26], although the latter studies are based on 
a limited number of subjects and are not well-controlled.  
The physiological function and importance of exercise-induced carnosine release by skeletal 
muscle remains to be determined, but could be diverse. Hypothetically, released carnosine 
by muscle could have a paracrine or endocrine hemodynamic function, as carnosine is 
shown to have vasodilatory [27] and venoconstrictive potential [28]. Carnosine has also been 
proposed to modulate the sympathetic nervous system, thereby affecting the autonomic 
control of the pancreas [20], kidney [29], adipose tissue [30] and blood pressure [29]. 
Possibly, for some of these actions, carnosine can exert its effect by serving as a precursor of 
histamine through histidine [31]. The carnosine-histidine-histamine pathway may be 
involved in the therapeutic effects of carnosine [32]. However, it could also be that the rapid 
hydrolysis of circulating carnosine is a disadvantage, as certain tissues need intact carnosine 
for protective purposes. It is in this context that we should interpret the findings of Janssen 
et al. [33]. They observed that a short allelic form of the carnosinase gene CNDP1 is 
associated with a lower serum carnosinase activity and with a decreased risk of diabetic 
nephropathy (Janssen et al. 2005). This suggests that the slower carnosine is hydrolyzed in 
the blood, the longer it can exert a protective effect in diabetes [34].  
Carnosine is predominantly present in skeletal muscle. Its abundance probably serves two 
functions, 1) to contribute to homeostatic control in other organs through carnosine release, 
and 2) to support local homeostasis in the muscle cells during contractions. The latter will be 
discussed in the following part. 
Role of carnosine in myocellular homeostasis 
Since most metabolites (ATP, phosphocreatine, glycogen, glutamine, carnitine,…) that have a 
high abundance in skeletal muscle cells are directly involved in energy transport and delivery, 
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initial searches for the role of carnosine in muscle were focussed on its possible role as a 
phosphagen system. Goodall [35] proposed that monophospho- and diphosphocarnosine 
function as a phosphate donor for ATP resynthesis during contractions. However, neither the 
phosphorylated forms of carnosine [36] nor a ‘carnosine kinase’ [37] have ever been 
detected in muscle tissue, and it is therefore unlikely that phosphocarnosine/carnosine plays 
a similar role as the phosphocreatine/creatine kinase system in energy delivery and storage 
in skeletal muscle [38]. Instead, a number of other biochemical properties of carnosine, 
mostly of the imidazole moiety of the histidine residue, have been described that can be of 
considerable value for contracting muscle cells.  
pH buffer 
The total intramyocellular buffering capacity is composed by the buffer actions of proteins, 
phosphates (Pi, CrP), ammonia, bicarbonate and histidine-containing dipeptides. Of all the 
amino acid side-chains in proteins, only the imidazole ring of histidine (pKa 6.1) has a good 
pKa to function as a pH buffer in the physiological range. The pKa is the acid dissociation 
constant and the pKa is ideal when it lies within the physiological pH range (6.5-7.1) of 
myocytes, so it can dynamically accept protons during contraction-induced acidosis. HCD are 
thought to be a way to up concentrate the content of histidine in muscle, as in proteins only 
1 out of 20 amino acids (on average) would be histidine, whereas in HCD this ratio is 1 out of 
2. Moreover, when bound to beta-alanine the pKa of histidine increases slightly to 6.83, 
which is right within the range of pH values that exist in contracting and fatigued myocytes. 
The role of carnosine as a physiologically relevant pH buffer was the first function of the 
dipeptide to be discovered [39;40]. Some fish species have no HCD in their muscles but 
instead display a very high concentration of free histidine (up to 100 mM in pelamyd or 
‘histidine fishes’, [5]), which suggests that one reason why carnosine is so abundant in 
muscles is to increase the histidine and imidazole content. 
Anti-oxidative potential, metal chelation and anti-glycation 
Carnosine can contribute to the defence against oxidative stress of tissues by directly 
interacting with reactive oxygen species (ROS). At physiological concentrations in muscle, 
carnosine can interact with singlet oxygen and scavenge peroxyl radicals [41] and superoxide 
radicals [42]. Therefore, carnosine can reduce the products of lipid peroxidation (TBARS, 
malondialdehyde) and act as a natural hydrophylic antioxidant [5;43;44].  
The mechanism for the anti-oxidative capacity may in part relate to the fact that carnosine 
can chelate ferrous ions and other transition metals [41]. Transition metals are known to 
promote the production of free radicals such as hydroxyl radical (OH˙) formation through the 
Fenton reaction. Carnosine can also form complexes with other divalent cations like copper 
and zinc. The importance of this property in muscle homeostasis remains to be determined, 
whereas in brain it has been shown that carnosine can protect against copper- and zinc-
induced neurotoxicity [45]. 
Glycation or non-enzymatic glycosylation describes the reaction of sugar aldehydes with 
amino groups of proteins which eventually leads to protein cross-linking and formation of 
advanced glycation end-products (AGEs). The latter may be involved in the aetiology of aging 
and diabetic complications [34]. In vitro studies have shown that carnosine can inhibit 
glycation and protein cross-linking in a sacrificial process of aldehyde scavenging [46]. 
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Carnosine has been implicated as a potential therapeutic adjuvant in a number of 
pathologies, such as cataract [47], aging [48] and diabetic complications [33], which may 
relate to carnosine’s biochemical properties of anti-glycation, anti-oxidation or metal 
chelation or a combination of these. 
Several other chemical properties of carnosine have been described, among others as an 
activator of carbonic anhydrase [49] and an inhibitor of angiotensin converting enzyme (ACE) 
[50]. The physiological relevance of these effects is not intensively studied and lies beyond 
the scope of this review. More extensive reviews on the chemical properties and 
therapeutical benefit of carnosine have previously been published [5;34;47;51;52]. 
Determinants of muscle carnosine content 
The concentration of carnosine in human muscle follows a Gaussian distribution (Figure 1) 
and is characterized by a high variation coefficient in soleus (27.5%) and gastrocnemius 
(27.6%). The currently available methods for quantification include invasive procedures, 
where dipeptides in muscle biopsy homogenates or fibers are separated and quantified by 
high-performance liquid chromatography (HPLC) [53;54], and a non-invasive procedure 
based on proton magnetic resonance spectroscopy (proton MRS) [1;55;56]. Both methods 
show similar effects of gender, beta-alanine supplementation, etc. on muscle carnosine 
content. The currently identified determinants of muscle carnosine content are graphically 
summarized in figure 2, and are described below. 
Fiber type 
In humans, fast-twitch muscle fibers have markedly higher carnosine content compared to 
slow-twitch fibers. The reported fast/slow concentration ratio, measured by HPLC-based 
single fiber analysis, varies from 1.3 to 2.0 [4;57;58]. As anaerobic energy delivery is 
quantitatively and qualitatively more important in glycolytic fibers, this pattern is in 
accordance with the supposed role of carnosine as a pH buffer. In most animal species a 
same fiber-type specific carnosine content in favour of fast-twitch fibers is observed [59;60]. 
Human skeletal muscles with a known high proportion of fast-twitch muscle fibers, such as 
gastrocnemius, have higher carnosine content than muscles with a typical slow-twitch 
profile, like soleus (figure 3). The strong correlation in figure 3 indicates that subjects with 
high carnosine content in one muscle will also have high values in the other skeletal muscles, 
and vice versa.  
Age and gender 
Mannion et al. [61] have compared the carnosine content of vastus lateralis muscles across 
gender and showed that men have approximately 20-25% higher muscle carnosine content 
than women, which is in line with their superior anaerobic performance capacity [62]. This 
could partly be caused by a higher proportion of fast-twitch fibers in male muscles [63], 
although there is no consensus regarding the latter [64]. Sexual dimorphism with respect to 
muscle carnosine and HCD content is species dependent, as it appears more pronounced in 
rodents [65], but is absent in the horse [66].  
Rodent skeletal muscle carnosine content markedly declines with advancing age [67;68]. A 
similar pattern is expected in humans although the current evidence is mainly based on 
cross-sectional comparisons with elderly with a specific pathology, such as osteoarthritis [69], 
neuromuscular disease [70] and glucose intolerance [71]. Advancing age is associated with a 
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gradual transition towards a slower muscle type, which could relate to the lower carnosine 
levels in the old. 
However, a more slow-twitch fibre type profile in the female and in the old can probably 
only account for a small portion of the gender and age effects on muscle carnosine content. 
More likely, androgens have a stimulating effect on muscle carnosine synthesis. Indeed, 
experiments in mice show that males have a 3-4 fold higher carnosine content than females 
and that in both genders the carnosine content is reduced by ~40% following gonadectomy 
[65]. Interestingly, the female muscle carnosine content can be elevated up to the level of 
males by exogenous testosterone administration. Although the extragonadal sexual 
dimorphism in mice is more pronounced than in humans, there is indirect evidence 
supporting a role for androgens in carnosine synthesis. In a descriptive study on body-
builders, where substance abuse with anabolic steroids is not unusual, very high muscle 
carnosine concentrations (approximately twice as high as in a control population) have been 
reported [72]. Also the well-described decline in androgen concentration with advancing age 
may be a determinant of the lower carnosine content of old muscle. If indeed androgens 
play an important role in muscle carnosine content, then it could be expected that a 
substantial elevation takes place in the maturation from boy to man. Data on humans are 
lacking, yet male but not female rodents show a doubling of muscle carnosine content 
during puberty [65]. 
Training status 
Parkhouse et al. [73] have cross-sectionally compared the carnosine concentration of the 
vastus lateralis of sprinters and rowers with marathoners and untrained. Sprinters (4.93 ± 
0.76 μmol/g) and rowers (5.04 ± 0.72) showed a markedly higher content than marathoners 
(2.80 ± 0.74) and untrained (3.75 ± 0.86) (p<0.01). Likewise, as shown in figure 4, trained 
400m-runners display higher carnosine concentrations than physically active students. These 
differences probably relate to both selection/genetic factors (such as fiber-type distribution) 
and to training-induced alterations in muscle carnosine content. 
Training intervention studies show differing results, depending on the training mode, as 
shown in table 1. Suzuki et al. [74] reported that the carnosine content of the vastus lateralis 
dramatically increased after 8 weeks of sprint training (1 or 2 Wingate cycling sprints per 
session, 2 sessions per week) from 5.17 ± 1.69 to 11.01 ± 3.05 mmol/kg wet muscle. Most 
other studies, however, do not report an increase in muscle carnosine content following 
different types of training. According to Kendrick et al. [75], 10 weeks (4 sessions per week) 
of resistance training did not change the carnosine content of the vastus lateralis. Also in 
response to isokinetic knee extensor training [58;76], no carnosine loading is observed. 
Although not intended as a training intervention study, Derave et al. [1] observed that the 
carnosine content in the gastrocnemius increased with 16% (p<0.05) in the placebo group, 
consisting of seven male trained 400m runners during a 5 week period while in preparation 
for the indoor competition season. In summary, the limited amount of training intervention 
studies available to date is equivocal with respect to the effects of exercise training on 
muscle carnosine content, but the effect of short-term training is probably small. 
The mechanism for the potential effects of chronic training on the carnosine content is to be 
elucidated. Hirakoba [77] proposes that the conditions of hypoxia and acidosis during high-
intensity exercise can be responsible for increased carnosine concentration in skeletal 
muscle. This point of view is nevertheless inconsistent with the research of Edge et al. [78]. 
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Their high-intensity interval training (6-12, 2-min intervals at 100% VO2max, with 1 min of 
rest between sets) performed 3 sessions per week for five weeks, resulted in a decrease of 
buffering capacity despite large exercise-induced decreases in muscle pH (pH=6.81). 
Moreover, the vision of Hirakoba [77] can not explain the differences in training effects, 
since both resistance training and isokinetic training can result in acidosis.  
Nutrition  
Carnosine can enter the circulation by intact absorption from the gut. The circulating 
carnosine concentrations are elevated for some time following the ingestion of HCD 
containing meat [25;79], but most of the dipeptide is hydrolysed by serum carnosinase 
within minutes to hours. The synthesis of carnosine in skeletal muscle is limited by the 
availability of beta-alanine rather than histidine [3;80]. Despite its designation as an essential 
amino acid, histidine occurs in sufficient concentrations in the circulation and will only limit 
carnosine synthesis in situations where a specific histidine-free diet is applied [81]. Beta-
alanine is not present in proteins and its main endogenous source is from the irreversible 
degradation of the pyrimidines uracil and thymidine. Postabsorptive circulating beta-alanine 
concentrations are therefore low. The transsarcolemmal transport of histidine and beta-
alanine provides the precursors for carnosine synthesis in skeletal muscle. 
The HCD content in the nutrition will have an impact on the availability of beta-alanine and 
therefore possibly on the muscle carnosine content. A vegetarian diet is free of HCD and an 
abstract reports that vegetarians have low muscle carnosine contents [82]. On the other 
hand, regular ingestion of chicken breast extract (CBEX), high in HCD content [83], is thought 
to elevate muscle carnosine content [84]. Between these extremes (vegetarianism on the 
one hand and systematic large intakes of CBEX on the other), it remains to be determined to 
what degree variation in the amount and type of daily meat intake influences the variation in 
muscle carnosine content between individuals.  
It was recently demonstrated that 15 weeks of oral creatine supplementation can 
substantially elevate muscle carnosine content in mice [68]. The mechanism for this 
phenomenon remains elusive at present. In humans, however, a carnosine loading effect of 
a short (1 week) period of oral creatine supplementation was not observed (Harris RC, 
personal communication). 
Beta-alanine supplementation  
Beta-alanine supplementation is probably one of the most powerful means to elevate 
muscle carnosine content (figure 2 and 4). The development of beta-alanine as a useful 
nutritional supplement has emerged from the elegant work of Roger C. Harris and co-
workers. They demonstrated, first in the horse [80] and later in humans [3], that the 
ingestion of large daily amounts (~100 mg/kg body weight) of beta-alanine is enough to 
elevate muscle carnosine content. Daily doses of 4.8 to 6.4 g of beta-alanine can elevate 
human muscle carnosine content with 60% in 4 weeks and 80% in 10 weeks [3;4]. Equimolar 
carnosine ingestion does not elevate muscle carnosine more than beta-alanine alone. Beta-
alanine supplementation increases muscle carnosine content in both type I and type II fibres 
[3]. When comparing between individuals, high initial carnosine levels do not seem to impair 
the effectiveness of muscle carnosine loading [1]. Likewise, sprint-trained athletes who have 
high initial carnosine levels respond equally well to beta-alanine supplementation, see figure 
4. Following cessation of beta-alanine supplementation, carnosine washout occurs at a slow 
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rate of 0.03 mM per day. An increase of 55% in muscle carnosine content was calculated to 
require a washout period of 15 weeks [2]. 
Fasting circulating beta-alanine concentrations are very low (<0.5 µM). When ingested in 
pure form, peak concentrations of beta-alanine appear in the blood within the first hour and 
rapidly decline within the second hour [3]. Doses of more than 10 mg/kg body weight are to 
be avoided, since circulating beta-alanine concentrations above 100 µM give rise to 
parasthesia symptoms, that probably relate to a sensitization of nociceptive neurons in the 
skin involved in neuropathic pain [85]. A daily dose of 4.8 to 6.4g therefore requires 6-8 
servings, separated by at least 2h. However, new controlled-release formulations of beta-
alanine are currently investigated, that display reduced peak concentrations and reduced 
parasthesia [86]. Apart from parasthesia, no other side effects of beta-alanine have been 
described so far [3]. Unlike creatine supplementation, beta-alanine does not induce body 
weight gain. Further research on the possible side effects and safety of beta-alanine as a 
nutritional supplement is warranted. 
Ergogenic effects of elevated muscle carnosine content 
Exercise types that benefit from beta-alanine supplementation 
Based on the observations that animals and humans that are performing well in sprint-type 
exercise have higher muscle carnosine content than those that excel in endurance exercise, 
it can be expected that high muscle carnosine content is ergogenic in anaerobic exercise, as 
first proposed by Parkhouse and McKenzie [87]. In 2002, Suzuki et al. [88] indicated that in a 
group of healthy men, high muscle carnosine contents correlated positively with the mean 
power per body mass (r=0.785, p<0.01) during a 30-s all-out cycling sprint, and especially in 
the latter phase of the exercise bout. 
Several recent investigations have explored the potential ergogenic effect of chronic beta-
alanine supplementation on different types of exercise performance, summarized in table 2 . 
Beta-alanine doses vary from 2 to 6.4 g.day-1 and durations from 3 to 13 weeks. 
In one of the first studies, Hill et al. [4] supplemented men for 10 weeks with 6.4 g.day-1 
beta-alanine. The total work done (TWD) during a cycle capacity test at 110% of their 
maximal power (duration of ~2.5 min) increased following 4 and 10 weeks of beta-alanine 
supplementation (+13% and +16.2% respectively). During an incremental cycling exercise 
test (starting at 40W and increasing with 20W every 3 min until exhaustion) in untrained 
women, Stout et al [89] found that the ventilatory threshold (+13.9%) and the time to 
exhaustion (+2.5%) significantly increased after 28 days of beta-alanine supplementation 
(6.4 g.day-1), although the VO2-max did not change. Also the physical working capacity at the 
fatigue threshold, determined by EMG of the vastus lateralis during cycling, increased 
significantly by beta-alanine supplementation in young [89] and aged [90] population. These 
studies were all performed in untrained subjects.  
In trained 400m-runners, 4-5 weeks of beta-alanine supplementation (4.8 g.day-1) did not 
improve 400m running performance more than in a placebo group despite a marked 
increase in muscle carnosine content [1]. However, during repeated isokinetic knee 
extensions (5x30 contractions with 1min rest intervals) beta-alanine reduced fatigue in the 
latter 2 bouts in this trained population. Whether beta-alanine is ergogenic in aerobic 
endurance exercise remains to be established. However, beta-alanine supplementation was 
15 
 
shown to improve the 30-s sprint capacity by 11% at the end of a 2-h simulated cycling race 
in moderately- to well-trained cyclists [91].  
The effect of beta-alanine supplementation on isometric knee extensor performance is 
equivocal. Ponte et al. [92] observed a 10-15% (8 seconds) improvement in isometric 
endurance at 45-50% of maximal voluntary contraction (MVC) of the knee extensors, 
whereas Derave et al. [1] could not identify an effect of oral beta-alanine supplementation 
on isometric endurance of the knee extensors at 45% of MVC. 
A single acute pre-exercise administration of a chicken breast extract (CBEX) soup 
(containing 1.5g of carnosine and anserine) does not improve performance during 
intermittent exercise that consisted of 10 x 5-s maximal cycle ergometer sprints with a 25-s 
recovery period between each sprint [84]. This finding supports the notion that the 
ergogenic effects of beta-alanine supplementation results from an increase in muscle 
carnosine content, which cannot be achieved by a single dose, but only following several 
weeks of supplementation. 
It can be concluded that chronic beta-alanine supplementation can have ergogenic effects 
during single or repeated bouts of high-intensity exercise or maximal contractions. Although 
the scientific evidence in untrained populations is substantial, more studies need to be 
conducted in trained populations and in various sport disciplines in order to fully understand 
the value of beta-alanine supplementation in performance enhancement in elite sports.   
Possible mechanisms of performance improvement 
The observed improvement in anaerobic exercise performance following beta-alanine 
supplementation is most likely related to the increased muscle carnosine content, inducing 
an attenuation of peripheral (rather than central) fatigue. This is supported by studies with 
isolated muscle preparations of frogs and rodents, that show reduced contractile fatigue 
when muscles are exposed to increased extracellular carnosine (a process termed Severin’s 
phenomenon [5;93;94]) or increased muscle carnosine content [68].  
Increased availability of carnosine in myocytes can improve contractile behaviour and 
reduce fatigue in several possible ways. Carnosine is indisputably a functional pH buffer. This 
is supported in a recent study by Derave et al. [95] on the effect of 4-5 week beta-alanine 
supplementation on exercise-induced acidosis in physically active students. The decline in 
circulating pH was significantly attenuated during a 6-min cycling exercise bout at an 
intensity of 50% of the difference between ventilatory threshold (VT) and VO2peak. The role 
of acidosis in muscular fatigue remains a matter of debate [96]. However, since both acute 
oral bicarbonate ingestion [97] and chronic beta-alanine supplementation have been shown 
to improve performance in exercise modes of similar duration and intensity, it is probably 
correct to conclude that at least part of the ergogenic effect of beta-alanine 
supplementation is related to improved physicochemical buffer capacity. However, the 
quantitative contribution of carnosine to total buffer capacity is limited, so it is likely that 
additional underlying mechanisms are at play. The initial estimates of carnosine’s 
contribution to total muscle buffer capacity were as high as 60% [39]. Later studies [61;98], 
however, estimated the contribution of carnosine to the total buffering capacity to be only  
7%.  
A second mechanism that is involved in muscle fatigue is the reduction in Ca2+ release from 
the sarcoplasmic reticulum (SR) [99]. Russian studies [100;101] have proposed that the 
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Severin’s phenomenon is explained by the modulation of SR Ca2+ release channel activity by 
carnosine. Specifically, carnosine could increase the sensitivity of Ca2+ release channels to 
their well-known activators (caffeine, AMP and Ca2+) and decrease the inhibitory effect of 
low concentrations of Mg+ [102]. However, Dutka and Lamb [103] could not support these 
findings. They demonstrated that the positive effect of carnosine on the contractile fatigue is 
due to increased Ca2+ sensitivity of the contractile machinery and not to facilitated 
Ca2+release. This effect was observed in chemically skinned fiber preparations of frog [104] 
as well as in mechanically skinned rat muscle fibers [103]. Thus, the increase of the Ca2+ 
sensitivity of the contractile apparatus by carnosine could aid in maintaining a higher level of 
force during the later stages of fatigue when Ca2+ release declines [103]. Mishima et al. [105]  
examined whether this carnosine-induced increase in Ca2+ sensitivity has any ergogenic 
effect on high-intensity exercise in rats. Despite an attenuation of the exercise-induced 
reduction in SR Ca2+ handling following 5 weeks of dietary chicken breast extract, the 
performance remained unchanged during high-intensity running for 2.5 minutes. It has to be 
noted that the evidence for the carnosine-stimulated increase in Ca2+ sensitivity is only 
based on in vitro and on rodent experiments and that the physiological in vivo evidence in 
human myofibers remains to be determined. 
A third possible mechanism of performance improvement evoked by carnosine could be 
related to its anti-oxidative potential. Skeletal muscle fibers continually generate reactive 
oxygen species (ROS) at a slow rate that increases during muscle contraction, which 
contributes to fatigue of skeletal muscle during intense and prolonged exercise [106]. Due to 
its anti-oxidative potential, an increased carnosine content could, theoretically, diminish this 
ROS accumulation. Indeed, the acute oral ingestion of 450mg carnosine can, after 1h but not 
after 2h, elevate the serum total antioxidant capacity in humans (expressed as µmol/l Trolox 
equivalents, by chemiluminescent assay) [107]. Another mechanism by which carnosine 
could diminish this ROS-induced fatigue could be related to its potential to increase the Ca2+ 
sensitivity, since reactive oxygen species can reduce the myofibrillar Ca2+ sensitivity in 
fatiguing mouse skeletal muscle [108]. However, it is clear that further research is 
recommended to verify the effects of prolonged ingestion of beta-alanine on oxidative stress 
evoked by muscle contractions in humans.  
Beta-alanine as a training aid 
Nutritional supplementation for athletes is not only useful in competition, but it can also be 
functional to optimize the training effects, e.g. by improving recovery, maintaining higher 
energy levels, optimizing the training adaptations, etc. [109]. In the literature there is 
disagreement whether the training-induced adaptations could be stimulated by beta-alanine 
supplementation. 
Several studies have investigated the effects of combined β-alanine supplementation and 
training on muscle and exercise performance, with conflicting results. According to Smith et 
al. [110], the effects of six weeks of high-intensity interval training on EMG-based 
neuromuscular fatigue in recreationally active men were not different between a control 
and a beta-alanine (3-6 g.day-1) supplemented group. In physical education students, the 
supplementation of 6.4 g.day-1 beta-alanine (10 weeks) did not have any additive effect 
compared to training alone on whole body strength, isokinetic force production, muscular 
endurance and body composition after 10 weeks of resistance training [75]. On the other 
hand Hoffman and colleagues [111] reported that collegiate football players, who are used 
17 
 
to strength and power training, improved strength and body composition after 10 weeks of 
resistance training in a group consuming both beta-alanine and creatine compared to the 
placebo and/or creatine group. Hofmann and colleagues [112] subsequently showed that 
the training volume of collegiate football players, during their preparation for the season, 
can be improved by the supplementation of beta-alanine (30 days, 4.5 g.day-1). The 
experimental group reached a significantly higher training volume in the bench press 
exercise and a trend for all resistance exercise sessions, combined with a better subjective 
feeling. In addition to the differences in initial training levels of the subjects, the higher 
volume and the possible synergistic effect of beta-alanine with creatine in the study of 
Hoffman et al. [111] could explain the inconsistency between these two comparable studies 
[75]. 
However, it seems that the performance enhancement of combined beta-alanine 
supplementation and training is smaller than the potential of creatine to stimulate training-
induced muscle hypertrophy. Nevertheless, it should be mentioned that training can 
stimulate the responsiveness to creatine supplementation [113;114], which is not the case 
with carnosine loading [58]. 
Practical implications for athletes 
There is a relatively high interindividual variation in skeletal muscle carnosine content 
between humans and carnosine is able to improve high-intensity exercise. Therefore, low 
muscle carnosine content in athletes may be disadvantageous for sprint performance. The 
carnosine content is determined by several factors, as depicted in figure 3. Oral beta-alanine 
supplementation is probably the most efficient way to increase the skeletal muscle 
carnosine content. Still, it must be noted that the effects of beta-alanine supplementation 
on the performance are small and probably only relevant to athletes who have already 
optimized the other training modalities and who are seeking a minor improvement in 
performance.  
The carnosine loading in muscle differs in several ways from the supplementation of the 
well-known creatine. Firstly, the loading of carnosine takes at least several weeks in contrast 
to the initial loading phase of one week for creatine. Conversely, also the washout rate is 
faster for creatine than for carnosine, indicating that the elevated muscle carnosine content 
is more stable [2]. A second difference with creatine supplementation is that individuals with 
a high initial muscle carnosine content, like sprint-trained athletes, respond equally well to 
beta-alanine supplementation as persons with a low initial content. In line with this apparent 
absence of a ceiling effect for carnosine, the highest reported supplementation-induced 
muscle loading is markedly higher for carnosine [4] than for creatine [115].  Finally, the 
supplementation of beta-alanine, in contrast to creatine, does not result in increased body 
mass which has important implications for athletes in weight-baring exercise types or weight 
class sports.  
Although both beta-alanine and bicarbonate have been suggested to attenuate exercise-
induced acidosis, there are marked differences between both ergogenic supplements 
[97;116]. First, sodium bicarbonate or citrate should be taken as an single pre-exercise dose, 
inducing acute metabolic alkalosis [117], whereas beta-alanine requires chronic 
supplementation for weeks, but does not affect the blood pH at rest. Beta-alanine is thought 
to work as a first-line defense as carnosine is elevated in the muscle cells where the protons 
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are produced during contractions, whereas bicarbonate resides in the circulation and only 
buffers once protons have entered the blood (second-line buffer). Additionally, bicarbonate 
elicits in many athletes a degree of gastro-intestinal discomfort, that does not occur with 
beta-alanine. 
Currently, no health-related side effects of the oral chronic supplementation of beta-alanine 
have been reported, except from the acute parasthesia that occurs when the prescribed 
maximum dose of 1g per 2h-period is exceeded (see ‘Beta-alanine supplementation’). A 
standard supplementation advice is to supplement 4 to 6.4 g.day-1 (divided over 0.8 to 1g 
servings) for at least 4 weeks. However, the effects on health of continuous beta-alanine 
supplementation beyond 10 weeks, as well as of its combination with other supplements 
remain to be established.  
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Conclusions and future directions for research 
In summary, it seems that the high interindividual variation in muscle carnosine content 
between humans is related to several determinants like muscle fiber type, age, gender, 
nutrition and training status. The underlying physiological mechanisms for this variation 
have to be elucidated. Another important question to be clarified is whether the high muscle 
carnosine levels of sprint-trained athletes are the result of the chronic effect of years of 
training or of selection effects and genetic factors. There are a number of indications that an 
elevated muscle carnosine content can delay fatigue during high-intensity exercise. Even 
though there is a shortage of available literature concerning the underlying mechanisms, 
especially in humans, it seems reasonable to assume that the performance improvement by 
beta-alanine supplementation is the result of carnosine’s potential to act as pH buffer, as a 
stimulator of the Ca2+ sensitivity and/or as antioxidant. Beside the ergogenic effects, 
carnosine probably contributes to homeostatic control in organs other than the muscle and 
to the susceptibility to certain diseases, but this research area is virtually unexplored at 
present.  
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Table 1: Effect of a training intervention on the carnosine content in the vastus lateralis. 
 
Reference Training type Training duration Subjects Muscle carnosine content 
(mmol/kg dm) 
Kendrick et al. 2008 
[75] 
Resistance training (4 
days/week) 
10 weeks 13 male physical 
education students 
PRE: 29.2 ± 9.82 
POST: 27.3 ± 9.52  
Kendrick et al. 2009 
[58] 
One-legged isokinetic training 
(4 days/week) 
4 weeks 7 physical education 
students 
PRE: 22.6 ± 2.1 
POST: 24.7 ± 3.7 
Mannion et al. 1994 
[76] 
Isokinetic knee extensor 
training (3 days/week) 
16 weeks 13 No statistical difference 
Suzuki et al. 2004 [74] Wingate sprint training 
(2days/week) 
8 weeks 6 untrained males PRE: 5.17±1.69 mM 
POST: 11.01±3.05 mM° 
°p<0.05 
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Table 2: Ergogenic effects of beta-alanine supplementation 
 
Reference Exercise  Supplementation Performance improved? Subjects 
Suzuki et al. 2006 
[84] 
10x 5s maximal cycle ergometer 
sprints, with a recovery of 25s 
CBEX (1.5g carnosine and anserine) 
Acute: 30min before exercise 
Total/ mean power: 
No 
Untrained males 
Ponte et al. 2006 
[92] 
Isometric knee extension at 45-
50% MVC until exhaustion 
6.4 g.day-1 β-alanine 
4 weeks 
Isometric: Yes Untrained males 
Derave et al. 2007 
[1] 
5 bouts of 30 maximal isokinetic 
knee extensions  
Isometric knee extension at 45% 
MVC until exhaustion 
400m race 
4.8 g.day-1 β-alanine 
4 weeks 
Isokinetic: Yes 
Isometric: No 
400m race: No 
Trained 400m 
athletes (males) 
Hill et al. 2007 [4] Cycle capacity test at 110% 
maximum power output 
6.4 g.day-1 β-alanine 
4-10 weeks  
Total work done: Yes Untrained males 
Stout et al. 2007 
[89] 
Continuous incremental cycle 
ergometry test to exhaustion  
Physical working capacity at fatigue 
threshold 
6.4 g.day-1 β-alanine 
4 weeks  
Time to exhaustion: 
Yes 
Physical working 
capacity: Yes 
Untrained females 
Stout et al. 2008 
[90] 
Physical working capacity at fatigue 
threshold 
2.4 g.day-1 β-alanine 
90 days 
Physical working 
capacity: Yes 
Aged men and 
women (73 ± 11y) 
Van Thienen et al. 
2009 [91] 
30s all out cycling at the end of 
simulated cycling race 
2 – 4 g.day-1 β-alanine 
8 weeks 
Peak and mean 
power output: Yes 
Moderate to well-
trained cyclists 
(males) 
 
